2019
The challenges of primary biliary cholangitis: What is new and what needs to be done
Terziroli Beretta-Piccoli B, Mieli-Vergani G, Vergani D, Vierling JM, Adams D, Alpini G, Banales JM, Beuers U, Björnsson E, Bowlus C, Carbone M, Chazouillères O, Dalekos G, De Gottardi A, Harada K, Hirschfield G, Invernizzi P, Jones D, Krawitt E, Lanzavecchia A, Lian ZX, Ma X, Manns M, Mavilio D, Quigley EM, Sallusto F, Shimoda S, Strazzabosco M, Swain M, Tanaka A, Trauner M, Tsuneyama K, Zigmond E, Gershwin ME. The challenges of primary biliary cholangitis: What is new and what needs to be done. Journal Of Autoimmunity 2019, 105: 102328. PMID: 31548157, DOI: 10.1016/j.jaut.2019.102328.Peer-Reviewed Original ResearchMeSH KeywordsAntibodies, AntinuclearAutoimmune DiseasesChenodeoxycholic AcidCholagogues and CholereticsCongresses as TopicFemaleHumansLiverLiver Cirrhosis, BiliaryUrsodeoxycholic AcidConceptsPrimary biliary cholangitisAnti-mitochondrial autoantibodiesBiochemical cholestasisBiliary cholangitisBiliary epitheliumUrsodeoxycholic acidPBC-specific anti-nuclear antibodiesBile acidsToxic hydrophobic bile acidsAutoimmune liver diseaseSecond-line treatmentFirst-line treatmentAnti-nuclear antibodiesReliable disease markersEarly disease stagesCholestatic biochemical profileNew therapeutic approachesHydrophobic bile acidsAutoimmune originSeronegative casesLiver histologyAutoimmune attackFemale preponderanceHistologic confirmationImmunologic pathways
2011
Loss of CFTR Affects Biliary Epithelium Innate Immunity and Causes TLR4–NF-κB—Mediated Inflammatory Response in Mice
Fiorotto R, Scirpo R, Trauner M, Fabris L, Hoque R, Spirli C, Strazzabosco M. Loss of CFTR Affects Biliary Epithelium Innate Immunity and Causes TLR4–NF-κB—Mediated Inflammatory Response in Mice. Gastroenterology 2011, 141: 1498-1508.e5. PMID: 21712022, PMCID: PMC3186841, DOI: 10.1053/j.gastro.2011.06.052.Peer-Reviewed Original ResearchMeSH KeywordsAnimalsAnti-Bacterial AgentsBile DuctsCholagogues and CholereticsCholangitisColitisCytokinesDextran SulfateDisease Models, AnimalEpithelial CellsHEK293 CellsHumansImmunity, InnateInflammation MediatorsKeratin-19Leukocyte Common AntigensLipopolysaccharidesMiceMice, Inbred C57BLMice, Inbred CFTRMice, KnockoutNeomycinNF-kappa BPhosphorylationPolymyxin BSrc-Family KinasesTime FactorsToll-Like Receptor 4TransfectionUrsodeoxycholic AcidConceptsCFTR KO miceBiliary epitheliumCystic fibrosisPortal inflammationBiliary damageInflammatory responseInnate immunityGut-derived bacterial productsTLR4 inhibitor TAK-242Toll-like receptor 4Cystic fibrosis transmembrane conductance regulatorInhibitor TAK-242Wild-type littermatesActivation of NFNuclear factor κBOral neomycinTLR4-NFTAK-242Liver damagePathogenetic roleBile flowDuctular reactionReceptor 4Cytokine secretionUrsodeoxycholic acid
1986
The Effect of Drugs on Bile Flow and Composition
Okolicsanyi L, Lirussi F, Strazzabosco M, Jemmolo R, Orlando R, Nassuato G, Muraca M, Crepaldi G. The Effect of Drugs on Bile Flow and Composition. Drugs 1986, 31: 430-448. PMID: 2872047, DOI: 10.2165/00003495-198631050-00003.Peer-Reviewed Original ResearchMeSH KeywordsAnimalsBileBile Acids and SaltsCatsChlorpromazineCholagogues and CholereticsCholesterolClofibrateColchicineCricetinaeDehydrocholic AcidDiureticsDogsEnterohepatic CirculationEstrogensGlucagonGuinea PigsHumansInsulinLiverMacaca mulattaPhospholipidsRabbitsRatsRifampinRifamycinsSomatostatinTheophyllineUrsodeoxycholic AcidConceptsBile flowBile acidsBile acid sequestrant cholestyramineBiliary bile acid secretionBiliary cholesterol concentrationBiliary cholesterol saturationBiliary cholesterol secretionBile acid concentrationsBile acid secretionBiliary phospholipid concentrationDrug-induced changesComposition of bileUnconjugated bile acidsEffects of drugsVariety of drugsCholesterol secretionHepatic secretionDrug therapyCholesterol saturationUrsodeoxycholic acidBiliary lipidsAcid secretionCholesterol concentrationsD-thyroxineHepatobiliary route